Efectividad y seguridad del doble balón intracervical, de la dinoprostona 10 mg y del misoprostol 25 mcg como métodos de inducción del parto en fetos CIR a término (peso fetal estimado en percentil <3 y estudio doppler normal)

  1. Duro Gómez, Jorge
unter der Leitung von:
  1. José Eduardo Arjona Berral Doktorvater/Doktormutter
  2. Camil Castelo-Branco Co-Doktorvater/Doktormutter

Universität der Verteidigung: Universidad de Córdoba (ESP)

Fecha de defensa: 20 von Juni von 2018

Gericht:
  1. Rafael Torrejón Präsident
  2. Sebastián Rufián Peña Sekretär/in
  3. Tirso Pérez Medina Vocal

Art: Dissertation

Zusammenfassung

Induction of labour is one of the most common techniques in today´s obstetrics. It is estimated that about 25 % of births begin this way. There are numerous techniques that have been used in order to trigger regular contractions and the expulsion of the fetusplacental unit. Almost all of these techniques can fall into two groups: medical or mechanical methods. In the first one, prostaglandins are included. In the second one, Foley catheter or double intracervical balloon (DIB) are some alternatives. Each of them has advantages and disadvantages that should be considered when using them in a particular patient. If the methods of induction are diverse, the lines that have been dedicated to them in the scientific literature are innumerable. The diversity in the methodology used by these papers makes impossible to draw universal conclusions, as well as guidelines of clinical practice common to all hospitals. For this reason, we try to study this exciting topic, focusing on a group of patients such as pregnant women with fetuses affected by intrauterine growth restriction (IUGR). According to its pathophysiology, we will try to compare misoprostol, dinoprostone and double intracervical balloon from the point of view of the effectiveness and costs associated with the technique. With these objectives, our results show prostaglandins as the most effective agents (time at birth) for induction of labour in IUGR fetuses with a similar safety profile as the DIB. Among them, 25mcg misoprostol is the most cost-effective agent for this group of patients.